Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development

scientific article published on 12 September 2019

Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.3390/PHARMACEUTICS11090472
P932PMC publication ID6781506
P698PubMed publication ID31547456

P50authorMing TanQ90231711
P2093author name stringXi Jiang
P2860cites workGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Q21534928
Emerging concepts in the immunopathogenesis of AIDSQ22241984
How does HIV cause AIDS?Q22242244
The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptorsQ24563224
Alzheimer amyloid hypothesis lives on.Q51229653
Enterovirus 71 infection: a new threat to global public health?Q82263969
Calicivirus VP2 forms a portal-like assembly following receptor engagementQ90971077
Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine PlatformQ91576751
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?Q92187571
Heterologous expression of human norovirus GII.4 VP1 leads to assembly of T=4 virus-like particlesQ92405713
Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cellsQ92560325
High-resolution cryo-EM structures of outbreak strain human norovirus shells reveal size variationsQ92641753
Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in miceQ92759295
Rotavirus and severe childhood diarrheaQ24605360
Structural basis for the recognition of blood group trisaccharides by norovirusQ24682901
World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data SynthesisQ26774950
X-ray crystallographic structure of the Norwalk virus capsidQ27619935
Insight into host cell carbohydrate-recognition by human and porcine rotavirus from crystal structures of the virion spike associated carbohydrate-binding domain (VP8*)Q27643845
Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host InteractionQ27656916
Crystallography of a Lewis-Binding Norovirus, Elucidation of Strain-Specificity to the Polymorphic Human Histo-Blood Group AntigensQ27671411
Crystal Structure of the Avian Astrovirus Capsid SpikeQ27678060
Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigenQ27678512
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeuticsQ27860914
Global burden of childhood pneumonia and diarrhoeaQ28288886
The changing epidemiology of astrovirus-associated gastroenteritis: a reviewQ28302569
Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's diseaseQ30835636
Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzleQ33341241
Alzheimer DiseaseQ33562441
Norovirus gastroenteritis, carbohydrate receptors, and animal modelsQ33701801
Subviral particle as vaccine and vaccine platformQ33812653
Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigsQ34059409
Branched-linear and agglomerate protein polymers as vaccine platformsQ34064413
Research and development of universal influenza vaccinesQ34093195
The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptorsQ34123964
Serological Correlate of Protection against Norovirus‐Induced GastroenteritisQ34153875
2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysisQ34227701
Structural requirements for the assembly of Norwalk virus-like particlesQ34335587
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer diseaseQ34376103
The pathogenesis of senile plaquesQ34421483
Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody ProductionQ34485266
Controlling influenza virus replication by inhibiting its proton channelQ34600414
Norovirus P particle efficiently elicits innate, humoral and cellular immunityQ34702360
Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particlesQ34724844
Norovirus-host interaction: multi-selections by human histo-blood group antigensQ35146233
Structure determination of feline calicivirus virus-like particles in the context of a pseudo-octahedral arrangementQ35201812
A candidate dual vaccine against influenza and norovirusesQ35301295
Aetiology-Specific Estimates of the Global and Regional Incidence and Mortality of Diarrhoeal Diseases Commonly Transmitted through FoodQ35859832
Serological Correlates of Protection against a GII.4 NorovirusQ35901978
Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific mannerQ35943850
Global Economic Burden of Norovirus GastroenteritisQ35999480
Rotavirus VP8*: phylogeny, host range, and interaction with histo-blood group antigensQ36246385
Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particlesQ36392947
Noroviral P particle: structure, function and applications in virus-host interactionQ36429481
Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virusQ36445296
A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirusQ36519453
Expression, self-assembly, and antigenicity of the Norwalk virus capsid proteinQ36685153
Polyvalent complexes for vaccine developmentQ36792270
Norovirus-host interaction: implications for disease control and preventionQ36876480
Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirusQ36914794
Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.Q36970026
A dual vaccine candidate against norovirus and hepatitis E virusQ37502688
A dual chicken IgY against rotavirus and norovirusQ37716268
Virus-like particle-based human vaccines: quality assessment based on structural and functional propertiesQ38152530
Histo-blood group antigens: a common niche for norovirus and rotavirusQ38194256
Progress toward norovirus vaccines: considerations for further development and implementation in potential target populationsQ38557262
Norovirus vaccines under developmentQ38698429
VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans.Q38714968
Recent advancements in combination subunit vaccine developmentQ38819439
Norovirus P particle: an excellent vaccine platform for antibody production against Alzheimer's diseaseQ40562871
Laboratory efforts to cultivate norovirusesQ40600126
Prestress strengthens the shell of Norwalk virus nanoparticles.Q40762621
A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in miceQ40925262
Elicitation of HIV-1 neutralizing antibodies by presentation of 4E10 and 10E8 epitopes on Norovirus P particlesQ41235708
Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected childrenQ41925938
Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometryQ46851930
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue9
P577publication date2019-09-12
P1433published inPharmaceuticsQ27723332
P1476titleNorovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development
P478volume11